Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Inhibikase Therapeutics (IKT) Times Interest Earned (2020 - 2022)

Inhibikase Therapeutics (IKT) has disclosed Times Interest Earned for 3 consecutive years, with -$928119.2 as the latest value for Q1 2022.

  • On a quarterly basis, Times Interest Earned fell 416962.55% to -$928119.2 in Q1 2022 year-over-year; TTM through Dec 2022 was -$3.6 million, a 489095.22% decrease, with the full-year FY2021 number at -$741.16, down 673.17% from a year prior.
  • Times Interest Earned was -$928119.2 for Q1 2022 at Inhibikase Therapeutics, down from -$31908.0 in the prior quarter.
  • In the past five years, Times Interest Earned ranged from a high of -$52.08 in Q2 2020 to a low of -$928119.2 in Q1 2022.
  • A 3-year average of -$109939.3 and a median of -$222.54 in 2021 define the central range for Times Interest Earned.
  • Peak YoY movement for Times Interest Earned: tumbled 205.98% in 2021, then plummeted 416962.55% in 2022.
  • Inhibikase Therapeutics' Times Interest Earned stood at -$168.21 in 2020, then crashed by 18869.2% to -$31908.0 in 2021, then plummeted by 2808.74% to -$928119.2 in 2022.
  • Per Business Quant, the three most recent readings for IKT's Times Interest Earned are -$928119.2 (Q1 2022), -$31908.0 (Q4 2021), and -$28478.0 (Q3 2021).